Literature DB >> 11057975

Epidemiological features of and public health response to a St. Louis encephalitis epidemic in Florida, 1990-1.

P J Meehan1, D L Wells, W Paul, E Buff, A Lewis, D Muth, R Hopkins, N Karabatsos, T F Tsai.   

Abstract

A St. Louis encephalitis (SLE) epidemic in Florida during 25 weeks in 1990-1, resulted in 222 laboratory-diagnosed cases, an attack rate in the 28 affected counties of 2.25/100,000. Disease risk rose with advanced age, to 17.14/100,000 in persons over 80 years, and all 14 fatal cases were in persons over 55 years (median, 70 years). Community serosurveys in Indian River County, the epicenter of the outbreak (attack rate 21/100,000), showed acute asymptomatic infections in 3.6% of the persons surveyed, with higher rates in persons with outdoor occupational exposure (7.4%) and in clients of a shelter for the indigent (13.3%). A matched case-control study found that evening outdoor exposure for more than 2 h was associated with an increased risk for acquiring illness (odds ratio [OR] 4.33, 95% CI 1.23-15.21) while a number of recommended personal protective measures were protective. Four SLE patients were dually infected with Highlands J virus, the first reported cases of acute infection with this alphavirus. The case-control study provided the first evidence that a public education campaign to reduce exposure had a protective effect against acquiring the disease.

Entities:  

Mesh:

Year:  2000        PMID: 11057975      PMCID: PMC2869585          DOI: 10.1017/s0950268899004227

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  9 in total

Review 1.  The contribution of rodent models to the pathological assessment of flaviviral infections of the central nervous system.

Authors:  David C Clark; Aaron C Brault; Elizabeth Hunsperger
Journal:  Arch Virol       Date:  2012-05-17       Impact factor: 2.574

2.  Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.

Authors:  Joseph E Blaney; James Speicher; Christopher T Hanson; Neeraj S Sathe; Stephen S Whitehead; Brian R Murphy; Alexander G Pletnev
Journal:  Vaccine       Date:  2008-06-13       Impact factor: 3.641

3.  Modifiable risk factors for West Nile virus infection during an outbreak--Arizona, 2010.

Authors:  Katherine B Gibney; James Colborn; Steven Baty; Andrean M Bunko Patterson; Tammy Sylvester; Graham Briggs; Tasha Stewart; Craig Levy; Ken Komatsu; Katherine MacMillan; Mark J Delorey; John-Paul Mutebi; Marc Fischer; J Erin Staples
Journal:  Am J Trop Med Hyg       Date:  2012-05       Impact factor: 2.345

4.  Predictors of human-infective RNA virus discovery in the United States, China, and Africa, an ecological study.

Authors:  Feifei Zhang; Margo Chase-Topping; Chuan-Guo Guo; Mark E J Woolhouse
Journal:  Elife       Date:  2022-06-06       Impact factor: 8.713

Review 5.  Diagnostic Approach for Arboviral Infections in the United States.

Authors:  Anne Piantadosi; Sanjat Kanjilal
Journal:  J Clin Microbiol       Date:  2020-11-18       Impact factor: 5.948

6.  Structure of the St. Louis encephalitis virus postfusion envelope trimer.

Authors:  Vincent C Luca; Christopher A Nelson; Daved H Fremont
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

Review 7.  North American encephalitic arboviruses.

Authors:  Larry E Davis; J David Beckham; Kenneth L Tyler
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

8.  Predictive mapping of human risk for West Nile virus (WNV) based on environmental and socioeconomic factors.

Authors:  Ilia Rochlin; David Turbow; Frank Gomez; Dominick V Ninivaggi; Scott R Campbell
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

9.  Global discovery of human-infective RNA viruses: A modelling analysis.

Authors:  Feifei Zhang; Margo Chase-Topping; Chuan-Guo Guo; Bram A D van Bunnik; Liam Brierley; Mark E J Woolhouse
Journal:  PLoS Pathog       Date:  2020-11-30       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.